This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Diabetic Nephropathy or Persistent Proteinuria With Type II Diabetes
and you are
between 18 and 75
years old
4
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

The DERENEDIAB study is a proof-of-concept, multi-center, prospective, open, randomized, controlled study of the effectiveness of renal denervation in addition to standardized medical treatment compared to medical treatment alone in diabetic subjects with diabetic nephropathy and resistant proteinuria. Bilateral renal denervation will be performed using the Symplicity Catheter - a percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.

Provided treatments

  • Procedure: Percutaneous renal denervation and TMNS
  • Drug: Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01588795. The sponsor of the trial is Assistance Publique - Hôpitaux de Paris and it is looking for 25 volunteers for the current phase.
Official trial title:
Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria